The main purpose of the Mayo Clinic Cancer Center Transgenic and Knockout (TKO) Shared Resource is to assist investigators at all 3 sites with the design and the generation of genetically modified mouse models. Utilization of the resource has been strong with 49 Cancer Center members from 8 different Programs using the Shared Resource during the current funding period (2013-2017). Our services include CRISPR/Cas9 mediated editing of genes of interest in fertilized mouse eggs to generate knockout and knock-in mouse models to inactivate or tag it, or to introduce point mutations, reporter genes, loxP sites or large deletions. Although gene editing by CRISPR/Cas9 is incredibly useful, in some instances it is not as robust as conventional gene targeting in embryonic stem (ES) cells, prompting us to maintain our classical services mainly to insert large (>5 kb) DNA fragments and loxP sites. Additional services offered by the TKO Core include founder screening, founder breeding, sperm cryopreservation, recovery of cryopreserved mouse strains through in vitro fertilization, and standard histopathology. TKO Shared Resource staff also provide advice on DNA preparation, mouse genotyping, handling and husbandry. To stay at the cutting edge of genome editing, the TKO devotes time and effort to develop or implement innovative and experimental procedures. The above activities allow Cancer Center members to implement state-of-the-art mouse models to address key open questions in the field of cancer etiology and to design and test new therapeutic approaches that improve cancer treatment outcome. The TKO Shared Resource achieved a score of Outstanding at the previous site visit.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Mayo Clinic, Rochester
United States
Zip Code
Kurmi, Kiran; Hitosugi, Sadae; Yu, Jia et al. (2018) Tyrosine Phosphorylation of Mitochondrial Creatine Kinase 1 Enhances a Druggable Tumor Energy Shuttle Pathway. Cell Metab 28:833-847.e8
O'Mara, Tracy A; Glubb, Dylan M; Amant, Frederic et al. (2018) Identification of nine new susceptibility loci for endometrial cancer. Nat Commun 9:3166
Wallace, Sumer K; Halverson, Jessica W; Jankowski, Christopher J et al. (2018) Optimizing Blood Transfusion Practices Through Bundled Intervention Implementation in Patients With Gynecologic Cancer Undergoing Laparotomy. Obstet Gynecol 131:891-898
Shrestha, Shikshya; Zhang, Cheng; Jerde, Calvin R et al. (2018) Gene-Specific Variant Classifier (DPYD-Varifier) to Identify Deleterious Alleles of Dihydropyrimidine Dehydrogenase. Clin Pharmacol Ther 104:709-718
Hu, G; Dasari, S; Asmann, Y W et al. (2018) Targetable fusions of the FRK tyrosine kinase in ALK-negative anaplastic large cell lymphoma. Leukemia 32:565-569
Geller, James I; Fox, Elizabeth; Turpin, Brian K et al. (2018) A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: A Children's Oncology Group phase 1 and pilot consortium trial (ADVL1315). Cancer 124:4548-4555
Luchtel, Rebecca A; Dasari, Surendra; Oishi, Naoki et al. (2018) Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements. Blood 132:1386-1398
Oishi, Naoki; Brody, Garry S; Ketterling, Rhett P et al. (2018) Genetic subtyping of breast implant-associated anaplastic large cell lymphoma. Blood 132:544-547
DuBois, Steven G; Mosse, Yael P; Fox, Elizabeth et al. (2018) Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma. Clin Cancer Res 24:6142-6149
Farber, Benjamin A; Lalazar, Gadi; Simon, Elana P et al. (2018) Non coding RNA analysis in fibrolamellar hepatocellular carcinoma. Oncotarget 9:10211-10227

Showing the most recent 10 out of 1129 publications